Immunic Inc (IMUX)

$0.92 +0.09 (10.51%)
Market Cap 81.81M
Revenue (ttm) 0.00
Net Income (ttm) -100.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,576,600
Avg Vol 1,668,460
Day's Range N/A - N/A
Shares Out 98.65M
Stochastic %K 55%
Beta 1.39
Analysts Strong Sell
Price Target $7.63

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 255 9818
Website: imux.com
Address:
1200 Avenue of the Americas, Suite 200, New York, United States
gertje1954
gertje1954 Aug. 14 at 7:31 PM
$IMUX shorts covering, nothing new. Not a sustainable raise
0 · Reply
master_yan
master_yan Aug. 14 at 7:30 PM
$IMUX I would have bought another share but I literally have 75 cents in my Schwab account.
1 · Reply
takingstock73
takingstock73 Aug. 14 at 7:13 PM
$IMUX wtf is the reason for this ?
1 · Reply
master_yan
master_yan Aug. 14 at 7:00 PM
$IMUX Sure, make me look like a complete twat.
1 · Reply
UF7
UF7 Aug. 14 at 6:50 PM
$IMUX
0 · Reply
Jw242
Jw242 Aug. 14 at 6:01 PM
$IMUX did Vitt fart or something?
1 · Reply
Jw242
Jw242 Aug. 14 at 2:46 PM
$IMUX more hugs for my longs
1 · Reply
master_yan
master_yan Aug. 14 at 2:28 PM
$IMUX Up half a penny!
1 · Reply
BadensBester
BadensBester Aug. 13 at 9:25 PM
$IMUX bought 8k shares @,82
1 · Reply
Stock_AHA
Stock_AHA Aug. 13 at 7:53 PM
$IMUX It was announced that approximately 30 million shares are owned by investment companies , equivalent to 30% of the total shares.. The number of people who believe in this company is increasing.. Is it possible that all of these people are risk-takers or do they know something for sure?
1 · Reply
Latest News on IMUX
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:30 AM EDT - 7 days ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 24, 2025, 6:30 AM EDT - 7 weeks ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 9, 2025, 5:51 PM EDT - 2 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 5, 2025, 6:30 AM EDT - 2 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 3, 2025, 4:01 PM EDT - 2 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Jun 2, 2025, 6:30 AM EDT - 2 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025, 7:05 AM EDT - 2 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. Announces Proposed Public Offering

May 28, 2025, 4:02 PM EDT - 2 months ago

Immunic, Inc. Announces Proposed Public Offering

Immunic to Participate in Scientific and Industry Conferences in May

May 2, 2025, 6:30 AM EDT - 3 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 28, 2025, 2:09 AM EDT - 3 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 10, 2025, 1:00 PM EDT - 4 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 4 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Apr 1, 2025, 6:30 AM EDT - 4 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Immunic to Participate in Scientific and Investor Conferences in March

Mar 3, 2025, 6:30 AM EST - 5 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 26, 2025, 6:30 AM EST - 6 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 20, 2025, 7:30 AM EST - 6 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic to Participate in Investor and Scientific Conferences in February

Feb 4, 2025, 6:30 AM EST - 6 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Jan 7, 2025, 6:30 AM EST - 7 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Immunic, Inc. to Participate in Investor Conference in December

Nov 26, 2024, 6:30 AM EST - 9 months ago

Immunic, Inc. to Participate in Investor Conference in December

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 13, 2024, 6:30 AM EST - 9 months ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:37 AM EST - 9 months ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:30 AM EST - 10 months ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 31, 2024, 6:30 AM EDT - 10 months ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 29, 2024, 6:30 AM EDT - 10 months ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Oct 22, 2024, 6:30 AM EDT - 10 months ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 11 months ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Immunic to Participate in Industry and Scientific Conferences in June

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Scientific Conferences in May

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Immunic to Participate in Investor and Scientific Conferences in March

Mar 7, 2024, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in March

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Feb 29, 2024, 6:30 AM EST - 1 year ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 3:38 PM EST - 1 year ago

Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Feb 22, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

Feb 15, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Jan 5, 2024, 6:35 AM EST - 1 year ago

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Immunic, Inc. Announces Private Placement of up to $240 Million

Jan 5, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Announces Private Placement of up to $240 Million

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

Nov 21, 2023, 6:30 AM EST - 1 year ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

gertje1954
gertje1954 Aug. 14 at 7:31 PM
$IMUX shorts covering, nothing new. Not a sustainable raise
0 · Reply
master_yan
master_yan Aug. 14 at 7:30 PM
$IMUX I would have bought another share but I literally have 75 cents in my Schwab account.
1 · Reply
takingstock73
takingstock73 Aug. 14 at 7:13 PM
$IMUX wtf is the reason for this ?
1 · Reply
master_yan
master_yan Aug. 14 at 7:00 PM
$IMUX Sure, make me look like a complete twat.
1 · Reply
UF7
UF7 Aug. 14 at 6:50 PM
$IMUX
0 · Reply
Jw242
Jw242 Aug. 14 at 6:01 PM
$IMUX did Vitt fart or something?
1 · Reply
Jw242
Jw242 Aug. 14 at 2:46 PM
$IMUX more hugs for my longs
1 · Reply
master_yan
master_yan Aug. 14 at 2:28 PM
$IMUX Up half a penny!
1 · Reply
BadensBester
BadensBester Aug. 13 at 9:25 PM
$IMUX bought 8k shares @,82
1 · Reply
Stock_AHA
Stock_AHA Aug. 13 at 7:53 PM
$IMUX It was announced that approximately 30 million shares are owned by investment companies , equivalent to 30% of the total shares.. The number of people who believe in this company is increasing.. Is it possible that all of these people are risk-takers or do they know something for sure?
1 · Reply
Bulltrader988
Bulltrader988 Aug. 13 at 6:55 PM
$IMUX 13G/A filled: Adage Capital Management, L.P. 10,479,337 shares = 9.99 % 👃👀 https://www.sec.gov/Archives/edgar/data/1280776/000090266425003508/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
Jw242
Jw242 Aug. 13 at 4:38 PM
$IMUX sector goes without us
0 · Reply
Jw242
Jw242 Aug. 13 at 3:21 PM
$IMUX group hug for us longs
0 · Reply
master_yan
master_yan Aug. 13 at 2:52 PM
$IMUX
0 · Reply
cbowers8171
cbowers8171 Aug. 13 at 2:52 PM
$IMUX is making it crystal clear they don’t care about retail or the share price. No partnership news. No funding clarity. No effort to support valuation. Just radio silence while the stock tanks. Great science doesn’t matter if the market loses faith. This is how you destroy retail confidence. What a joke.
1 · Reply
royer356
royer356 Aug. 13 at 2:31 PM
$IMUX how many days in a row has this dropped now? Pretty depressing
0 · Reply
GeneralGatsby22
GeneralGatsby22 Aug. 13 at 2:28 PM
$IMUX yikes…cmon I sold my $AMPX shares to max you out and you do me like this? Sheesh
0 · Reply
Jw242
Jw242 Aug. 13 at 2:23 PM
$IMUX Vitt needs to buy a ton of crypto
0 · Reply
Starflash
Starflash Aug. 13 at 2:05 PM
$IMUX This stock is driving me mad.
1 · Reply
MRCHECKDATIMESTAMP
MRCHECKDATIMESTAMP Aug. 13 at 8:36 AM
$RVPH Strong upside setup, liquidity, biotech $IMUX High-rated, potential for big breakout $ZOOZ Crypto pivot story—watch as thematic signal
0 · Reply
takingstock73
takingstock73 Aug. 13 at 1:16 AM
$IMUX steady climb from here
4 · Reply
Jw242
Jw242 Aug. 12 at 2:20 PM
$IMUX good times
1 · Reply